Phase IIb A dose ranging study was conducted to determine the optimal dose of Oncosil. Six patients were enrolled in London (UK) and Birmingham (UK) and received either 200Gy or 400Gy as a single injection. The study was completed in August 2009.
Product safety No clinically significant product-related adverse events. No significant systemic leakage of ( 32P), from the site of implantation.
Product efficacy CT scan analysis of patients demonstrated significant tumouricidal activity with a disease control rate of 100%. Optimized Dose The highest dose studied, 400Gy (4 times the dose used in the Phase IIa trial) was determined to be the optimal dose.
Forgive me for being slow but with such good data from the IIb trial in 2009, why didn't they continue with a phase III, almost immediately. And why offload this for $1ook.
Something does not smell right, or have I completely misinterpreted the data points?
OSL Price at posting:
16.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)